SUMO-1 CRISPR Knockout and Activation Products (h)

SUMO-1 CRISPR Knockout and Activation Plasmids (h) designed to edit, knockdown or upregulate human SUMO-1 gene expression

Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells

Recombinant Anti-Sumo 1 antibody [Y299] - ChIP Grade KO Tested (ab32058)

Reciprocal interplay between OTULIN–LUBAC determines genotoxic and inflammatory NF-κB signal responses

CRISPR/Cas advancements for genome editing, diagnosis, therapeutics, and vaccine development for Plasmodium parasites, and genetic engineering of Anopheles mosquito vector - ScienceDirect

CRISPR/Cas9-mediated genome editing of PML in human cell lines. (A) The

Sumoylation of Cas9 at lysine 848 regulates protein stability and DNA binding

SUMO-4 CRISPR Knockout and Activation Products (h)

CRISPR-Cas knockout of miR21 reduces glioma growth: Molecular Therapy - Oncolytics

SUMO-4 CRISPR Knockout and Activation Products (h)

Alternative CRISPR Discovered @MIT Leaders in Pharmaceutical Business Intelligence (LPBI) Group